What is Imvax?
Imvax operates at the intersection of oncology and immunology, focusing on the development of sophisticated therapeutic solutions for complex cancers. Its flagship program, IGV-001, represents a significant advancement in the treatment of glioblastoma, a notoriously difficult-to-treat form of brain cancer. By utilizing a unique platform that captures the full spectrum of tumor antigens, Imvax distinguishes itself from traditional targeted therapies that often address only a single mutation. This holistic approach to immunotherapy positions the company as a critical player in the biotech sector, with a clear focus on improving patient outcomes through precision medicine and innovative biological engineering.
How much funding has Imvax raised?
Imvax has raised a total of $195.7M across 5 funding rounds:
Unspecified
$14.7M
Series A
$15M
Series B
$25M
Series C
$112M
Other Financing Round
$29M
Unspecified (2017): $14.7M, investors not publicly disclosed
Series B (2019): $25M, investors not publicly disclosed
Series A (2019): $15M, investors not publicly disclosed
Series C (2020): $112M featuring Magnetar Capital, Invus, TLP Investment Partners, Ziff Capital Partners, and HP WILD Holding AG
Other Financing Round (2025): $29M, investors not publicly disclosed
Key Investors in Imvax
Magnetar Capital
Magnetar Capital is a prominent financial investment firm based in Evanston, IL, with a deep focus on hedge fund strategies and complex debt market instruments.
Invus
Invus Group is a New York-based investment firm established in 1985 that provides strategic financial advice and capital services to high-growth enterprises.
TLP Investment Partners
TLP Investment Partners is an institutional investor participating in the strategic financing of high-potential biotechnology ventures.
What's next for Imvax?
With the successful closure of this major enterprise-level funding, Imvax is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic allocation of this capital will likely focus on scaling the manufacturing processes for its immunotherapy candidates and supporting the rigorous clinical trials required for regulatory approval. As the company moves into its next phase of growth, the focus will remain on validating the efficacy of IGV-001 and exploring the broader applicability of its platform technology across various solid tumor indications. Investors and industry observers will be closely monitoring the company's progress as it navigates the complex regulatory environment and works toward commercializing its transformative medical solutions.
See full Imvax company page
